Related
Topics
Therapies
Immunoadsorption
Indications
KidneyHeartSkinBrain

IgEnio®

A treatment option for removing IgE

IgEnio® is a flexible therapy option for patients suffering from severe stages of allergic symptoms. It selectively removes type IgE antibodies from the plasma in a single treatment. IgEnio® presents a valuable therapy option for patients with high IgE levels, where conventional treatments prove ineffective.

IgEnio IgE adsorberIgEnio® IgE adsorber

The distinctive characteristics of IgEnio®

  • Well-defined: based on a well-defined anti-IgE single-chain fragment1
  • Selective: only removes IgE, leaving IgM and IgG immunoglobulins unaffected1
  • Single-pass: easy handling without column regeneration during the treatment1
  • Single-use: therapeutic apheresis without the need for preservation between treatments1
  • Compatible: fully compatible with Fresenius Kabi COM.TEC® and other centrifuge systems1
  • In the ESPIRA study, the IgEnio® adsorber was combined with the Fresenius Kabi COM.TEC® cell separator to perform a specific type of immunoapheresis (IA) in patients with severe atopic asthma. IgE levels in patients treated with IgEnio® were clearly reduced after each cycle, whereas IgE levels in the control group were stable.2

IgEnio® achieved an average IgE-reduction of 88% per cycle (including three treatments)2

Mean IgE levels during cycle one of the ESPIRA study2

IgEnio® uses a specific ligand with high affinity for IgE

After separation from other blood components, the plasma is passed through the IgEnio® adsorber column, where IgE binds to ScFv12. ScFv12 is an anti-IgE antibody-derived single-chain fragment with a high affinity for human IgE.

ESPIRA study resultsAbove: chart adapted from ESPIRA study.
Adverse events were successfully controlled by standard medication in all cases and treatment could be reliably performed.2

Benefits of treatment with IgEnio®

  • Single-use adsorber with a specific IgE ligand from a recombinant single-chain variable fragment1
  • Average IgE reduction of 86% in the ESPIRA study2
  • Flexible patient treatment scheme1
  • A clinical setup simply requires a centrifuge (e.g., Fresenius Kabi COM.TEC®) for plasma generation3

Clinical setup

Treatment setup for IgEnio® simply requires a centrifuge (e.g., Fresenius Kabi COM.TEC®) for plasma generation.

Clinical setup for IgEnioClinical setup for IgEnio® Adapted from Lupinek C et al2

References

  1. IgEnio® - Instructions for use
  2. Lupinek C et al, Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy (ESPIRA Study), EBioMedicine, Mar. 2017; 17: 119–33.
  3. IgEnio® Preparation Kit - Instructions for use

Related therapies

ImmunoadsorptionImmunoadsorption